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Abstract
The mechanisms by which tumors are able to evade
cellular immune responses are still largely unknown. It
is likely, however, that the initial recruitment of
lymphocytes to tumor vessels is limited by cell
retention in normal tissue, which results in a low flux
of these cells into the tumor vasculature. We grew
MCaIV (mouse mammary carcinoma) tumors in the leg
of SCID mice and injected 111In-oxine–labeled, primed
T lymphocytes directed against the tumor intrave-
nously. The systemic distribution of cells in normal
organs was similar between mice injected with primed
and control lymphocyte populations, except for a
delayed clearance of primed lymphocytes from the
lungs. Kinetics of lymphocyte localization to the tumor
were identical between the primed and control lympho-
cyte populations. Splenectomy before the injection of
primed lymphocytes increased delivery of cells to the
lungs and liver after 1 hour with no significant improve-
ment in tumor localization. Within 24 to 168 hours after
injection, localization of cells in the liver of splenec-
tomized mice was higher than in the control group.
However, no significant difference in tumor localization
was observed between groups. A physiologically based
compartmental model of lymphocyte distribution pre-
dicted the compartmental sequestration and identified
model parameters critical for experimental planning
and therapeutic optimization.
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Introduction
Significant progress has been made in understanding the
nature of the immune response to tumors and the role of
tumor antigens in this process [1–3,4]. In some cases
lineage-specific differentiation antigens may be expressed in
the tumor cell population, providing potential targets for
activated lymphocytes [5,6 ]. Recognition of a tumor-
associated antigen is likely to depend on recognition of the
dominant epitopes as observed in both human [7] and
murine [8] systems. However, the importance of lymphocyte
specificity in the initial recruitment of antitumor effector cells
remains unclear. Does lymphocyte localization in a tumor
require specific recognition of tumor antigen in the vascular
compartment or is initial recruitment dependent on the
characteristics of the tumor-associated vasculature? Tumor
infiltration by lymphocytes, monocytes, and eosinophils is
common [9], especially at the tumor periphery [10,11].
Although the presence of tumor-specific lymphocytes within
tumor tissue suggests specific recruitment, it may also reflect
a more generalized process of recruitment involving cells of
multiple specificities and lineages.
The ability of the leukocyte population to identify tumor-
associated antigens and kill the cells that express them is not
sufficient to effect a complete antitumor response in most
patients. One possible reason for this may be insufficient
homing of cells with required specificity to the tumor tissue.
Although tumor localization of cultured tumor- infiltrating
lymphocytes has been demonstrated [12], it appears that in
some cases the number of delivered cells was inadequate to
produce a therapeutic response. Adoptive immunotherapy
with lymphokine-activated and expanded effector cells, such
as interleukin-2 ( IL-2)–activated tumor- infiltrating lympho-
cytes, has had limited success in advanced patients with
cancer [1,13–15], yet the mechanism of delivery remains
unclear. In vitro findings and limited in vivo data suggest that
the tumor-specific cytolytic activity of the effector cells is
preceded by the delivery of effector cells to the target tissues
[16–18]. If the ability of lymphocytes to eradicate an
established tumor is determined by the tumor burden, growth
pattern, and the intensity of the immune response at the site
of tumor [16,17,19–22], the antitumor response may be
insignificant when the delivery of a specific cytotoxic cell
population to a developing tumor is limited.
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BRIEF ARTICLE
Delivery of cells to a tumor may be influenced by at
least three different factors: cellular adhesion molecule
(CAM) expression within the tumor vasculature, the flux
of circulating cells entering the tumor microcirculation, and
the ability of the leukocyte population to engage the
appropriate CAMs to arrest and extravasate into the
tissue [23]. The present study uses experimental and
mathematical models to quantify trafficking of injected




Mouse antitumor lymphocytes were prepared from
immunization of Balb /c mice (H-2 d, Mls b ) with lympho-
cytes from C3H/sed mice (H-2 k, Mls c ). Briefly, C3H mice
were sacrificed and their spleens were removed and placed
in culture medium RPMI 1640 (Fisher Scientific, Pittsburgh,
PA) with 10% FCS (Gibco, Grand Island, NY). Single-cell
suspensions were prepared by disruption of the spleens
followed by lysis of the erythrocytes in distilled water. The
resulting cells were resuspended in saline and exposed to
three freeze–thaw cycles. The resulting material was
washed once in PBS, mixed with Freunds incomplete
adjuvant and refrozen at 708C. Aliquots were removed
and injected into the Balb/c mice at 1-week intervals for
3 weeks. The resulting sensitized lymphocyte populations
were obtained by removal of spleens from the donor
populations. Single cell suspensions were prepared as
before. The mononuclear population was washed once in
culture medium and depleted of the monocyte population
through column adhesion for 1 hour at 378C. The cells
were then eluted with three volumes of warm medium,
washed once and examined. Giemsa staining of the
cytofuged cells revealed that 98% of the cells in the final
cell suspension were small lymphocytes.
Tumor Model
The syngeneic carcinoma, MCaIV, was grown in female
C3H mice. The MCaIV cell line was maintained by in vivo
passage from frozen stock and only low passage tumors
( less than five passages) were used. Cells were collected
from harvested tumors, washed once in complete medium,
and resuspended in medium without serum to a concen-
tration of approximately 108/ml. A volume of 10 to 20 l
was injected subcutaneously in the leg of an SCID (H-2 d,
Mls b ) mouse. Within 8 days, this procedure resulted in
tumors of 0.7-cm diameter. The leg tumor model was
selected for this study because (a) the tumor is distant
from the internal organs, simplifying interpretation of the
results and (b) it provides convenient access for monitor-
ing growth. In one group of mice, splenectomy was
performed (after anesthesia with ketamine, 9 mg/100 g,
and xylazine, 0.9 mg/100 g i.m.) under aseptic conditions.
Tumor implantation was performed 3 to 5 days following
surgery.
Cell Labeling
111In oxine was incubated with the sensitized or non-
sensitized lymphocytes for 1 hour at 378C. The cells were
then washed with PBS three times and resuspended to a
concentration of 107 cells /150 l. Total activity of the cells
was checked in a gamma-counter before use (approx-
imately 100 Ci /107 cells ). Because of variable release
rates of In from labeled cells, we used a previously optimized
labeling procedure in which In oxine was synthesized and
purified de novo before each labeling procedure; optimum
ratios of cell / isotope and incubation times were used, cells
were repeatedly washed before injection ( to remove not
transchelated oxine), and nonviable cells were excluded
from the injectate [24,25].
Cell Injection and Imaging Procedure
Ten minutes before injection of the cell suspension, the
mice were given a mixture of ketamine (9 mg/100 g) and
xylazine (0.9 mg/100 g) intramuscularly. After anesthesia, a
heparinized (100 IU/ml) 30-gauge cannula was placed into
the lateral tail vein. A 1-ml syringe containing 107 labeled
cells in 0.15 ml PBS was connected to the intravenous line
and the cells were injected over approximately 1 minute.
Imaging of cell localization was initiated 1 hour after injection
and continued at 24-hour intervals. Imaging was performed
using a gamma camera (Ohio Nuclear, Solon, OH) with a
pinhole collimator and a 37 PMT array. Images were
assembled and quantified on a Macintosh computer using
the NucLear Power 2.9 software. Regions of interest (ROIs)
were determined at the time of the initial imaging procedure
and remained constant throughout the subsequent time
points. Counts obtained from the ROIs were adjusted for
isotope decay at each time point. Counts obtained in the liver
and spleen were adjusted to compensate for proximity by
removing the organs and comparing relative counts in the
liver and spleen using a gamma counter. The counts
obtained by planer scintigraphy were adjusted by the relative
distribution of total counts in these organs. In a separate
subgroup of mice, imaging findings were validated by
performing comparative biodistribution studies at multiple
endpoints.
Confirmation of Sensitization
Specificity of the lymphocyte preparation was tested by
proliferation assay (Promega, Madison, WI). Both tumor
antigen and sensitizing antigen were used to elicit a
proliferative response. Concanavalin A and medium were
used as positive and negative controls, respectively. Tumor
antigen was obtained from sterile homogenized MCaIV
tumor (F3 passage from frozen stock), which was immedi-
ately frozen. Tumor homogenate was diluted 1:100 in fresh
culture medium before use.
Immunohistology
Tumor tissue was removed from mice that were not used
for imaging studies. Normal skin was obtained from non–
tumor-bearing mice for comparison. Tissue samples were
placed in plastic tissue trays and embedded in OCTmedium,
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then quick- frozen in isopropanol and dry ice. Frozen
sections were cut at 7-m thickness and fixed in cold
acetone (48C) for 5 minutes. The sections were washed
once with PBS, pH 7.2, with 1%BSA (Sigma, St. Louis, MO).
The slides were then stained in a humidified chamber at 378C
for 30 minutes using 5 l of anti– ICAM-1-biotin (01542D,
Pharmingen, San Diego, CA), anti– ICAM-2-biotin
(01802D, Pharmingen), anti–VCAM-1-biotin (01812D,
Pharmingen), anti–CD31-biotin (01952D, Pharmingen) or
PBS alone. Following incubation, the slides were washed
three times with PBS with 1% BSA, then incubated for 30
minutes with 10 l of avidin-alkaline phosphatase (104
dilution, A-7294, Sigma) at 378C. The slides were washed
three times with PBS/1% BSA, then incubated with 0.1 ml of
Fast Red TR/naphthol AS-MX reagent in Tris buffer (F-
4523, Sigma). The slides were washed three times with
distilled water and counterstained lightly with hematoxylin
(HHS-16, Sigma). The slides were then washed once in
distilled water and the coverslips weremounted with glycerol.
Mathematical Model
The basis of the theoretical model used in these studies
has been described previously [26]. Briefly, the model
simulates the following key processes involved in lympho-
cyte trafficking following adoptive transfer: (1) transport
through the systemic circulation, (2) initial reversible capture
( temporary adhesion or entrapment) at the endothelial wall,
(3) arrest (stable adhesion) at the endothelial wall following
capture, (4) transmigration of arrested lymphocytes across
the endothelial wall, (5) recirculation through the lymphatic
system following transmigration in organ compartments, (6)
limited recirculation in tumor compartment, (7) transient
accumulation of recirculating lymphocytes in the lumped
lymph node before return to the systemic circulation, and (8)
possible depletion ( for example, mechanical disruption or
apoptosis) in tissues. The model assumed that free labels
were excreted through urine at a much faster rate than their
spontaneous release from cells, rendering their influence on
the observed biodistribution negligible. Lymphocyte prolifer-
ation during the distribution phase was also neglected. The
major lymphoid tissues included in the model were bone
marrow, spleen, and lymph node. In addition to the lymphoid
tissues, other peripheral organs and tissues such as blood,
heart, lung, liver, kidney, GI tract, skin, muscle, and tumor
were incorporated in the model. These organs and tissues
were arranged according to their anatomic relationship. The
simulations were performed as described previously varying
certain parameter values as appropriate to simulate the
difference between normal and sensitized cell populations.
Results and Discussion
Systemic and Tumor Distributions
The general pattern of lymphocyte distribution following
injection was similar for all mice used in these studies.
Lymphocyte localization in the lungs peaked immediately
after injection and dropped to between 1% and 10% of the
injected cell number within 24 hours. Redistribution of these
cells at 24 hours post injection resulted in a concurrent
increase in liver and spleen localization, which remained
stable throughout the observation period. Lymphocyte local-
ization within the tumor ranged from 1% to 2.5% (4 to 7 days
post injection).
Sensitized and normal lymphocyte populations were
tested for proliferation in response to stimulation by
sensitizing antigen, tumor homogenate or Concanavalin A
(Figure 1 ). Lymphocyte proliferation in response to both
tumor and sensitizing antigen was equal to the mitogenic
response to Concanavalin A, indicating successful priming.
Scintigraphic studies of cell biodistribution revealed that
tumor-specific and nonspecific lymphocytes had approxi-
mately equal levels of delivery to the tumor during the first
week following administration (Figure 2;A and B ). Although
this finding suggests a diminished importance of antigen
specificity for tumor rejection [1], the number of lymphocytes
in the injected population that were specific for the foreign
antigen may have been relatively low and below the ability of
our system to distinguish them from the labeled nonspecific
lymphocytes. However, using similar methods, Kjaergaard
and Shu [27] were also able to show that lymphocyte
specificity is not a major determinant of localization. These
results further suggest that the initial phase of cell recruit-
ment to tumors is nonspecific.
Our previous studies of NK cell localization in tumors also
indicated that some tumor vessels support adhesive
interactions with injected effector cells [28]. However, a
second stage of recruitment, mediated by the infiltrating T-
cell population may be required to initiate tumor rejection.
Unfortunately, the isotope half - life (2.8 days) restricted the
duration of these studies to a week, preventing observation
of the longer- term kinetics.
Because both the liver and spleen act as principal
retention sites for injected lymphocyte populations, we
hypothesized that removal of one of these compartments
would alter the distribution of the injected populations.
Figure 1. Sensitization of H -2 d mice (Balb / c ) with H -2 k (C3H ) antigen.
Cell proliferation assays indicate that sensitized T lymphocytes from H-2 d
mice proliferated in response to H -2 k antigen expressed on tumor cells or
spleen cells to levels comparable with a nonspecific mitogen (maximal
stimulation ). Approximately the same level of cell proliferation ( as indicated by
the staining intensity of the assay ) could be observed between cells
stimulated with tumor cells, spleen cells, and Concanavalin A mitogen.
Means±SD of five wells are shown.
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Removal of the spleen (Figure 2C ) resulted in increased
uptake within the liver as early as 1 hour after cell injection.
Increased retention by the liver was approximately equal to
the expected uptake by the missing spleen. These findings
suggest that modification of compartmental localization of
injected cells can alter distribution but does not provide a
dramatic improvement in tumor delivery.
Comparison with Pharmacokinetic Model
The mathematical model was used to simulate lympho-
cyte distribution in mice, both with and without splenec-
tomy. All administered cell populations were assumed to
have an equal probability of tumor localization and no bias
was given to retention of lymphocyte subpopulations within
various microvascular or lymphatic compartments. The
model predicted the initial lymphocyte uptake in lungs and
the subsequent redistribution to the liver and spleen
(Figure 2;A and B ). Lymphocyte retention rates were
slightly overestimated for the liver and spleen, resulting in
higher values than observed. However, the model predicted
well the overall trends in the biodistribution profiles with time
and was able to capture the increased liver uptake following
splenectomy. The agreement between model predictions
and experimental data (Figure 2;A C ) supports the validity
of the assumption that different lymphocyte populations have
an equal likelihood of recruitment by the tumor vasculature.
The expression of constitutive and inducible CAMs on
normal endothelium in vitro and in vivo is tissue/organ
dependent [29]. Several CAM expression studies in tumor
vessels have been conducted ( for a review, see Ref. [30] )
and these studies demonstrate that CAM expression
during tumor angiogenesis is highly heterogeneous. Varia-
tion in CAM expression can be observed within different
tumor types, and within different regions of the same
tumor. Human mammary cancer endothelium, for example,
shows increased expression of various adhesion molecules
(e.g., E-selectin, VCAM-1, and ICAM-3) [31], whereas in
primary melanomas and various other tumors, VCAM-1
expression is focal or downregulated [32]. These findings
help to explain how the heterogeneous infiltration of
leukocytes into tumors can occur in terms of variation in
adhesion of cells to tumor vessels. Although other
mechanisms contribute to the migration and activity of
infiltrating leukocytes within tumors, the accumulation of
cells within the tumor vessels is an initial limiting factor on
the system.
Immunohistology performed on sections from the MCaIV
tumor demonstrated moderate staining for ICAM-1, ICAM-
2, and CD31 but strong staining of VCAM-1 throughout the
tumor tissue, indicating the potential for 1 integrin–
mediated adhesion in these vessels (Table 1). We have
shown [28,33] preferential adhesion of IL-2–activated
natural killer (A-NK) cells in some vessels within human
and murine (MCaIV) tumors. This suggests that the relative
Figure 2. Experimental and theoretical biodistribution profiles of sensitized
(A ) and normal (B ) lymphocyte populations in tumor -bearing mice and in
tumor -bearing mice with splenectomy (C ). Overall patterns of systemic
distribution and accumulation of lymphocytes within the tumors were
similar for both populations of lymphocytes, suggesting that the initial
phase ( <7 days ) of cell recruitment to tumors may be nonspecific.
Splenectomy of mice before the implantation of the tumor results in tumor
accumulation kinetics comparable to the nonsensitized lymphocyte
populations in the nonsplenectomized mice. Retention of transferred
lymphocytes within the liver is greater than in nonsplenectomized mice,
suggesting a shift in compartmental distribution following the removal of a
major filtration compartment, but only a slight increase in tumor localization
can be observed. Means±SD are shown, n = 6 mice / group. The
simulations of the mathematical model are shown overlying the exper-
imental data. The predictions agree well with the experiments and capture
the salient features of the experimental biodistribution profiles.
Table 1. Expression of Cellular Adhesion Molecules in the MCaIV Tumor and
Normal Skin
Antibody Tumor tissue* Normal tissue
Isotype control  
ICAM-1 + +
ICAM-2 + +
VCAM-1 + + + + 
CD31 + + + +
*Results indicate expression observed on frozen sections of tissue and
stained by immunohistology.
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degree of lymphocyte interaction with tumor and normal
vessels depends on the regional variation in adhesion
molecule expression within the tumor. Further insight into
lymphocyte binding to tumor vessels has come from PET
studies of the localization of IL-2 A-NK cells in normal and
tumor tissues in mice [34]. These findings are in agreement
with the current observation that lymphocyte localization to
tumor vessels is adhesion and delivery dependent. That
these previous studies were performed with A-NK cell
populations precludes antigen-specific recognition mecha-
nisms for localization and supports a nonspecific adhesion
mechanism for the accretion of lymphocytes within a tumor.
Populations of NK cells may have high affinity to regions of
tumor vessels [28,33], but may be limited to a single pass
through (or around) the tumor vasculature due to entrap-
ment in other organs [35]. In contrast, T lymphocytes may
have lower adhesion efficiencies to the tumor vessels but are
not limited to single-pass delivery. It is reasonable that T
cells may localize within tumor vessels through a similar
adhesive mechanism, using repeated recirculation of the
tumor-specific cells to facilitate long- term accumulation of
lymphocytes within tumors. The parallels between the
kinetics of lymphocyte localization and the model simulations
(Figure 2;A C ), in which all injected cell populations were
assumed to be recruited to the tumor vasculature with equal
probability, supports the hypothesis of nonspecific recruit-
ment of lymphocytes to a tumor.
Modulation of Biodistribution
We have previously shown that modulation of lympho-
cyte-endothelial adhesion accompanies angiogenesis [36].
The extent to which this will influence the accumulation of
lymphocytes within the tumor depends on the number of cells
in the tumor microcirculation available for recruitment. The
data from this study and the mathematical simulations of
lymphocyte biodistribution (Figure 2 ) indicate that high
retention of lymphocytes within the liver and spleen restricts
the availability of a large fraction of the injected cells for
recruitment to the tumor. Although lymphocytes within these
organs may still be available for recirculation, the rate at
which this occurs appears to be low, because the number of
cells within the liver is constant after 72 hours. Removal of
the spleen does not increase the number of cells available for
tumor recruitment because these are acquired and retained
by the liver, as observed experimentally and predicted by the
theoretical model. Thus, our work suggests that improved
lymphocyte delivery to tumors will require increased sys-
temic availability of circulating lymphocytes at steady state to
facilitate adhesion and infiltration of tumor-specific T-cell
populations.
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